Natco Pharma (NSE:NATCOPHARM) E10: ₹56.32 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
88 GF Score
Price ₹877.50
GF Value ₹825.42
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma E10?

Natco Pharma NSE:NATCOPHARM -1.05% 88 E10 is ₹56.32 as of Jun. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 88/100 and a GF Value™ of ₹825.42 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Natco Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹11.530. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹56.32 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Natco Pharma's average E10 Growth Rate was 14.60% per year. During the past 3 years, the average E10 Growth Rate was 25.00% per year. During the past 5 years, the average E10 Growth Rate was 21.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Natco Pharma was 25.30% per year. The lowest was 10.00% per year. And the median was 20.95% per year.

As of today (2026-08-21), Natco Pharma's current stock price is ₹877.50. Natco Pharma's E10 for the quarter that ended in Jun. 2026 was ₹56.32. Natco Pharma's Shiller PE Ratio of today is 15.58.

During the past 13 years, the highest Shiller PE Ratio of Natco Pharma was 50.70. The lowest was 15.28. And the median was 27.83.


Natco Pharma  (NSE:NATCOPHARM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Natco Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=877.50/56.32
=15.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Natco Pharma was 50.70. The lowest was 15.28. And the median was 27.83.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Natco Pharma E10 Related Terms


Natco Pharma E10 Historical Data

* Premium members only.

The historical data trend for Natco Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma E10 Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.40 27.95 35.86 46.19 54.56

Natco Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.16 52.57 53.37 54.56 56.32

NSE:NATCOPHARM vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Shiller PE Ratio falls into.


NSE:NATCOPHARM
88GF Score
Natco Pharma Ltd NSE:NATCOPHARM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Natco Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.53/167.3573*167.3573
=11.530

Current CPI (Jun. 2026) = 167.3573.

Natco Pharma Quarterly Data

per share eps CPI Adj_EPS
201609 3.780 105.961 5.970
201612 11.160 105.196 17.755
201703 10.090 105.196 16.052
201706 5.580 107.109 8.719
201709 4.820 109.021 7.399
201712 12.250 109.404 18.739
201803 16.210 109.786 24.710
201806 9.820 111.317 14.764
201809 9.860 115.142 14.331
201812 8.673 115.142 12.606
201903 6.610 118.202 9.359
201906 7.850 120.880 10.868
201909 6.530 123.175 8.872
201912 5.730 126.235 7.597
202003 5.150 124.705 6.911
202006 6.730 127.000 8.869
202009 11.090 130.118 14.264
202012 3.430 130.889 4.386
202103 2.900 131.771 3.683
202106 4.110 134.084 5.130
202109 3.570 135.847 4.398
202112 4.400 138.161 5.330
202203 -2.770 138.822 -3.339
202206 17.550 142.347 20.633
202209 3.110 144.661 3.598
202212 3.410 145.763 3.915
202303 15.100 146.865 17.207
202306 23.260 150.280 25.903
202309 20.600 151.492 22.757
202312 11.880 152.924 13.001
202403 21.560 153.035 23.578
202406 37.320 155.789 40.091
202409 37.810 157.882 40.079
202412 7.430 158.323 7.854
202503 22.700 157.552 24.113
202506 26.840 159.755 28.117
202509 28.940 162.289 29.844
202512 8.460 163.281 8.671
202603 14.960 164.272 15.241
202606 11.530 167.357 11.530

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹56.32 mean?
Natco Pharma (NSE:NATCOPHARM) has a E10 of ₹56.32 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's E10 too high?
Natco Pharma's current E10 is ₹56.32. Overall, Natco Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's E10 compare to ZTS?
Natco Pharma's E10 of ₹56.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Natco Pharma and its competitors. Natco Pharma's current E10 is ₹56.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹825.42, compared to a current price of ₹877.50 — trading 6.3% above its estimated fair value. The current E10 is ₹56.32. Natco Pharma's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current E10 is ₹56.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued. The current stock price of ₹877.50 is trading 6.3% above its estimated GF Value™ of ₹825.42. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • E10: ₹56.32
  • GF Value™: ₹825.42 vs. price of ₹877.50 (6.3% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
88GF Score

Get the complete analysis for NSE:NATCOPHARM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹877.50
Price
₹825.42
GF Value